Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe : the PanCareSurFup study
(2023) In British Journal of Cancer 128(1). p.80-90- Abstract
Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results: One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia... (More)
Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results: One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6–25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3–44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6–23.7). Conclusions: Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early.
(Less)
- author
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Cancer
- volume
- 128
- issue
- 1
- pages
- 80 - 90
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85141153732
- pmid:36319851
- ISSN
- 0007-0920
- DOI
- 10.1038/s41416-022-02016-w
- language
- English
- LU publication?
- yes
- id
- 640a2d4a-ad47-4dbe-90ae-e6ea0d04659a
- date added to LUP
- 2022-12-21 12:24:49
- date last changed
- 2024-10-04 09:50:48
@article{640a2d4a-ad47-4dbe-90ae-e6ea0d04659a,
abstract = {{<p>Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results: One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6–25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3–44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6–23.7). Conclusions: Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early.</p>}},
author = {{Sunguc, Ceren and Hawkins, Michael M. and Winter, David L. and Dudley, Isabelle M. and Heymer, Emma J. and Teepen, Jop C. and Allodji, Rodrigue S. and Belle, Fabiën N. and Bagnasco, Francesca and Byrne, Julianne and Bárdi, Edit and Ronckers, Cécile M. and Haddy, Nadia and Gudmundsdottir, Thorgerdur and Garwicz, Stanislaw and Jankovic, Momcilo and van der Pal, Helena J.H. and Mazić, Maja Česen and Schindera, Christina and Grabow, Desiree and Maule, Milena M. and Kaatsch, Peter and Kaiser, Melanie and Fresneau, Brice and Michel, Gisela and Skinner, Roderick and Wiebe, Thomas and Sacerdote, Carlotta and Jakab, Zsuzsanna and Gunnes, Maria Winther and Terenziani, Monica and Winther, Jeanette F. and Lähteenmäki, Päivi M. and Zaletel, Lorna Zadravec and Kuehni, Claudia E. and Kremer, Leontien C. and Haupt, Riccardo and de Vathaire, Florent and Hjorth, Lars and Reulen, Raoul C.}},
issn = {{0007-0920}},
language = {{eng}},
number = {{1}},
pages = {{80--90}},
publisher = {{Nature Publishing Group}},
series = {{British Journal of Cancer}},
title = {{Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe : the PanCareSurFup study}},
url = {{http://dx.doi.org/10.1038/s41416-022-02016-w}},
doi = {{10.1038/s41416-022-02016-w}},
volume = {{128}},
year = {{2023}},
}